Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sapporo Clinical Laboratory Inc. (9776:JPX), powered by AI.
Sapporo Clinical Laboratory Inc. is currently trading at ¥1,952. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Sapporo Clinical Laboratory Inc. on Alpha Lenz.
Sapporo Clinical Laboratory Inc.'s P/E ratio is 13.2.
“Sapporo Clinical Laboratory Inc. trades at a P/E of 13.2 (undervalued) with modest ROE of 4.2%.”
Ask for details →Sapporo Clinical Laboratory Inc. operates as a key player in the healthcare industry, focusing on providing clinical testing services essential for medical diagnostics and healthcare solutions. This company specializes in offering a wide range of medical examinations, including biochemical tests, hematological analysis, and microbiological assessments, serving both hospitals and medical practitioners. By delivering precise and timely diagnostic information, Sapporo Clinical Laboratory supports the healthcare sector in ensuring accurate disease diagnoses and effective treatment planning. As healthcare demands continue to grow, the company’s role is increasingly pivotal, contributing significantly to public health management and patient care improvement. Based in Sapporo, Japan, the company combines advanced laboratory technology with expert knowledge to maintain high standards in clinical diagnostics. This commitment not only fortifies its market presence but also elevates its impact within the broader healthcare infrastructure, particularly in Japan, where there is an ongoing emphasis on improving healthcare quality and accessibility.
“Sapporo Clinical Laboratory Inc. trades at a P/E of 13.2 (undervalued) with modest ROE of 4.2%.”
Ask for details →Sapporo Clinical Laboratory Inc. (ticker: 9776) is a company listed on JPX in the Healthcare sector (Pharmaceutical Retailers). It has approximately 879 employees. Market cap is $6.1B.
The current price is 1,952 with a P/E ratio of 13.16x and P/B of 0.55x.
ROE is 4.20% and operating margin is 3.51%. Annual revenue is $20.1B.